| Index | — | P/E | — | EPS (ttm) | — | Insider Own | 0.35% | Shs Outstand | 49.25M | Perf Week | -21.59% |
| Market Cap | 330.95M | Forward P/E | — | EPS next Y | -2.29 | Insider Trans | 26.96% | Shs Float | 36.45M | Perf Month | -21.50% |
| Enterprise Value | 194.95M | PEG | — | EPS next Q | -1.06 | Short Float | 2.58% | Perf Quarter | -54.38% | ||
| Income | -71.00M | P/S | — | EPS this Y | — | Short Ratio | 6.73 | Perf Half Y | -44.51% | ||
| Sales | 0.00 | P/B | 2.15 | EPS next Y | — | ROA | -12.26% | Short Interest | 941.90K | Perf YTD | -54.29% |
| Book/sh | 3.13 | P/C | 2.42 | EPS next 5Y | — | ROE | -19.70% | 52W High | 17.82 -62.29% | Perf Year | — |
| Cash/sh | 2.78 | P/FCF | — | EPS past 3/5Y | — | ROIC | -11.76% | 52W Low | 6.52 3.07% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 13.03% 8.68% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.89 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 12.88 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 24.65 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 12.88 | EPS Q/Q | 98.05% | SMA20 | -21.22% | Beta | 1.76 | Target Price | — |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -37.72% | Rel Volume | 0.71 | Prev Close | 7.49 |
| Employees | 62 | LT Debt/Eq | 0.01 | Earnings | Mar 03 | SMA200 | -44.35% | Avg Volume | 149.57K | Price | 6.72 |
| IPO Date | Feb 06, 2026 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -175.49% — | Net Debt/EBITDA | — | Volume | 105,630 | Change | -10.28% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-22-26 | Initiated | H.C | Buy |
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | |
| Gross Profit | 0 | 0 | 0 | — | |
| Selling, General and Administrative Excl. Other | 14 | 11 | 6 | — | |
| Research and Development | 55 | 43 | 28 | — | |
| Other Operating Expense | -2 | -2 | 0 | — | |
| Operating Income | -67 | -52 | -34 | — | |
| Interest Expense | 0 | 0 | 0 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | -4 | 2 | 21 | — | |
| Net Income Before Taxes | -71 | -50 | -13 | — | |
| Income Taxes | 0 | 0 | -1 | — | |
| Consolidated Net Income | -71 | -50 | -12 | — | |
| Net Income From Continuing Operations | -71 | -50 | -12 | — | |
| Net Income | -71 | -50 | -12 | — | |
| EPS (Recurring) | -1.44 | -1.36 | -0.34 | — | |
| EPS (Basic, Before Extraordinaries) | -1.44 | -1.36 | -0.34 | — | |
| EPS (Diluted) | -1.44 | -1.36 | -0.34 | — | |
| EBITDA | -70 | -50 | -13 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | — | — | — | |
| Operating Margin | — | — | — | — | |
| Net Margin | — | — | — | — | |
| Shares Outstanding | 49 | 36 | 36 | — | |
| Market Capitalization | — | — | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Epstein David R | Director | Oct 21 '26 | Buy | 8.88 | 10,000 | 88,800 | 25,000 | Oct 22 |
| Epstein David R | Director | Oct 08 '26 | Buy | 8.90 | 5,000 | 44,500 | 15,000 | Oct 09 |
| Kemula Pierre Thadee Victor | Chief Financial Officer | Oct 06 '26 | Buy | 8.59 | 10,000 | 85,940 | 10,000 | Oct 07 |
| Epstein David R | Director | Oct 06 '26 | Buy | 8.70 | 5,000 | 43,500 | 10,000 | Oct 07 |
| Knotnerus Tim Jasper | Chief Executive Officer | Oct 06 '26 | Buy | 8.70 | 5,000 | 43,500 | 21,823 | Oct 07 |
| Knotnerus Tim Jasper | Chief Executive Officer | Oct 05 '26 | Buy | 8.48 | 6,000 | 50,880 | 16,823 | Oct 07 |
| Epstein David R | Director | Oct 05 '26 | Buy | 8.57 | 5,000 | 42,850 | 5,000 | Oct 07 |